Results 111 to 120 of about 21,216 (279)

Feline leukaemia virus (FeLV) infection in domestic pet cats in Australia and New Zealand: Guidelines for diagnosis, prevention and management

Australian Veterinary Journal, Volume 103, Issue 10, Page 617-635, October 2025.
Progressive feline leukaemia virus (FeLV) infection dramatically shortens the lives of infected cats, causing acquired immunodeficiency, aplastic anaemia, lymphoma, leukaemia and other myeloproliferative diseases. The potential impact of regressive FeLV infection on the development of disease remains largely unknown, although there is evidence it ...
ME Westman, SJ Coggins, M van Dorsselaer, JM Norris, RA Squires, M Thompson, R Malik   +6 more
wiley   +1 more source

HIV/HCV-coinfection: which role can new antiretrovirals such as integrase inhibitors play?

European Journal of Medical Research, 2009
End-stage liver disease has become one of the most frequent causes of death in HIV/HCV-coinfected patients. The role of new antiretrovirals in the progression of liver fibrosis has yet to be defined.
Vogel Martin, Nelson Mark
doaj   +1 more source

Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort

HIV Medicine, 2019
The aim of the study was to assess the rates of discontinuation of integrase inhibitor regimens because of any neuropsychiatric adverse event (NPAE) and the factors associated with discontinuation.
J. Llibre, A. Montoliu, J. Miro, P. Domingo, M. Riera, J. Tiraboschi, A. Curran, F. Homar, J. Ambrosioni, N. Abdulghani, L. Force, J. Peraire, J. Casabona, Joaquim Vilaró, À. Masabeu, A. Ortí, D. Dalmau, J. Reyes, A. Bruguera, A. Montoliu, E. Muntada, D. Podzamczer, G. Navarro, C. Cortes, V. Falcó, J. Mallolas, C. Manzardo, A. Imaz, J. Burgos, M. Gracia Mateo, M. Gutierrez, J. Murillas, F. Segura, M. García-Gasalla, T. Puig, F. Vidal, E. Leon, A. Jaen, A. Almuedo, E. de Lazzari, D. Giralt, M. Martin, F. Gargoulas, T. Vanrell, J. Rubia, J. Vilà, M. Ferres, B. Morell, M. Tamayo, M. Laguno, M. Martínez, J. L. Blanco, F. García-Alcaide, E. Martínez, A. Jou, B. Clotet, M. Saumoy, A. Silva, P. Prieto, J. Navarro, E. Ribera, M. Gurguí, M. A. Ribas, A. Campins, F. Fanjul, M. Leyes, M. Peñaranda, L. Martin, H. Vilchez, S. Calzado, M. Cervantes, J. Amengual, M. Navarro, T. Payeras, C. Cifuentes, T. Comella, M. Vargas, C. Viladés, P. Barrufet, I. Chivite, E. Chamarro, C. Escrig, M. Cairó, X. Martínez-Lacasa, R. Font, E. Deig, S. Meyer, J. Hernández   +87 more
semanticscholar   +1 more source

Differential effects of dolutegravir, bictegravir and raltegravir in adipokines and inflammation markers on human adipocytes.

Life Science, 2022
P. Domingo, T. Quesada-López, J. Villarroya, M. Cairó, M. Gutiérrez, M. Mateo, Isabel Mur, Noemí Corbacho, J. Domingo, F. Villarroya, M. Giralt   +10 more
semanticscholar   +1 more source

Modern antiretroviral regimens

Медицинский совет, 2016
The article presents the results of major international studies (STARTMRK, ACTG A5257, SPRING 2, the SINGLE and FLAMINGO), which convincingly demonstrated the effectiveness and safety of drugs from the group of integrase inhibitors (raltegravir and ...
A. V. Kravchenko
doaj   +1 more source

Evaluation of Neural Tube Defects (NTDs) After Exposure to Raltegravir During Pregnancy

Journal of Acquired Immune Deficiency Syndromes, 2019
Objective: To evaluate the risk of neural tube defects (NTDs) after exposure to raltegravir during pregnancy. Methods: Exposures to raltegravir during pregnancy reported cumulatively through May 31, 2018, to the company safety database were reviewed to ...
H. Shamsuddin, Casey Raudenbush, Brittany Sciba, Yun-ping Zhou, T. Christopher Mast, Wayne L. Greaves, George J. Hanna, Ronald W Leong, W. Straus   +8 more
semanticscholar   +1 more source

Assessment of second-line antiretroviral regimens for HIV therapy in Africa. [PDF]

, 2014
BACKGROUND: The efficacy and toxic effects of nucleoside reverse-transcriptase inhibitors (NRTIs) are uncertain when these agents are used with a protease inhibitor in second-line therapy for human immunodeficiency virus (HIV) infection in resource ...
Abongomera, George, Abwola, Mary, Alima, Hillary, Arribas, Jose R, Atwongyeire, Dickens, Boles, Justine, Chidziva, Ennie, EARNEST Trial Team, Easterbrook, Philippa J, Hakim, James, Hoppe, Anne, Kambugu, Andrew, Kiconco, Mary, Kityo, Cissy, Lugemwa, Abbas, Mambule, Ivan, Mugyenyi, Peter, Mwebaze, Raymond, Mweemba, Aggrey, Nyirenda, Rose, Paton, Nicholas I, Reid, Andrew, Siika, Abraham, Thompson, Jennifer, Tumukunde, Dinah, van Oosterhout, Joep J, Walker, A Sarah   +26 more
core   +1 more source

Budget impact analysis in the maintenance raltegravir-containing regimen in virologically suppressed HIV infected patients

Global & Regional Health Technology Assessment, 2017
Budget impact analysis in the maintenance raltegravir-containing regimen in virologically suppressed HIV infected patientsBackgroundA one-year cost analysis was conducted to estimate the impact from the perspective of the Italian National Health Service (
Roberto Ravasio, Mauro Maresca, Barbara Busà, Benedetto Maurizio Celesia   +3 more
doaj   +1 more source

An Allosteric Mechanism for Inhibiting HIV-1 Integrase with a Small Molecule [PDF]

, 2009
HIV-1 integrase (IN) is a validated target for developing antiretroviral inhibitors. Using affinity acetylation and mass spectrometric (MS) analysis, we previously identified a tetra-acetylated inhibitor (2E)-3-[3,4-bis(acetoxy)phenyl]-2-propenoate-N ...
Burke, Terrence R., Jr., Eidahl, Jocelyn O., Hess, Sonja, Kessl, Jacques J., Kvaratskhelia, Mamuka, McKee, Christopher J., Shkriabai, Nikolozi, Zhao, Zhuojun   +7 more
core   +3 more sources

A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study)

PLoS ONE, 2019
Background Very few data are available on treatment in HIV Late presenter population that still represents a clinical challenge. Methods Prospective, multicenter, randomized open-label, 2 arm, phase-3 trial comparing the 48-week virological response of ...
C. Mussini, E. Roncaglia, V. Borghi, S. Rusconi, S. Nozza, A. Cattelan, D. Segala, P. Bonfanti, A. di Biagio, E. Barchi, E. Focà, A. D. Degli Antoni, S. Bonora, D. Francisci, Silvia Limonta, A. Antinori, G. d’Ettorre, F. Maggiolo   +17 more
semanticscholar   +1 more source